Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.66 |
| ▸ | CCR3 | P51677 | 1/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.59 |
| ▸ | DRD2 | P14416 | 1/20 | 0.56 |
| ▸ | DRD4 | P21917 | 1/20 | 0.56 |
| ▸ | DRD3 | P35462 | 1/20 | 0.56 |
| ▸ | MC4R | P32245 | 1/20 | 0.55 |
| ▸ | BCHE | P06276 | 1/20 | 0.54 |
| ▸ | BACE1 | P56817 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | ABL1 | P00519 | 1/20 | 0.52 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14519153 | 0.94 | ACHE (0.58) | ACHECCR3SIGMAR1DRD2DRD4 | |
| SCHEMBL13676574 | 0.90 | ACHE (0.57) | ACHECCR3SIGMAR1DRD2DRD4 | |
| SCHEMBL13676573 | 0.90 | ACHE (0.57) | ACHECCR3SIGMAR1DRD2DRD4 | |
| SCHEMBL13005299 | 0.90 | ACHE (0.57) | ACHECCR3SIGMAR1DRD2DRD4 | |
| SCHEMBL7852368 | 0.88 | ACHE (0.64) | ACHECCR3SIGMAR1DRD2DRD4 | |
| SCHEMBL20012633 | 0.86 | ACHE (0.62) | ACHECCR3SIGMAR1DRD2DRD4 | |
| SCHEMBL4636684 | 0.86 | ACHE (0.62) | ACHECCR3SIGMAR1DRD2DRD4 | |
| SCHEMBL19770184 | 0.86 | ACHE (0.62) | ACHECCR3SIGMAR1DRD2DRD4 | |
| SCHEMBL19879957 | 0.86 | ACHE (0.67) | ACHECCR3SIGMAR1DRD2DRD4 | |
| SCHEMBL7651915 | 0.86 | ACHE (0.62) | ACHECCR3SIGMAR1DRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 165 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4389121-A1 | ANTIVIRAL AMINO ACID DERIVATIVES | Consejo Superior De Investigaciones Científicas (CSIC) (ES) | 2024-06-26 | — | — | EP | disclosed |
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C 4 Therapeutics, Inc. (US) | 2024-01-18 | — | — | US | disclosed |
| US-20230381142-A1 | ANTILEISHMANIAL COMPOUNDS, COMPOSITIONS AND USE THEREOF | TRUSTEES OF BOSTON UNIVERSITY (US) | 2023-11-30 | — | — | US | disclosed |
| US-20230381142-A1 | ANTILEISHMANIAL COMPOUNDS, COMPOSITIONS AND USE THEREOF | TRUSTEES OF BOSTON UNIVERSITY (US) | 2023-11-30 | — | — | US | disclosed |
| US-20230365530-A1 | QUINAZOLINE-2,4-DIAMINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING SAME AS ACTIVE INGREDIENT | OMIC SMAP INC. (KR) | 2023-11-16 | — | — | US | disclosed |
| US-20230365530-A1 | QUINAZOLINE-2,4-DIAMINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING SAME AS ACTIVE INGREDIENT | OMIC SMAP INC. (KR) | 2023-11-16 | — | — | US | disclosed |
| WO-2023183886-A2 | COMPOSITIONS FOR AND METHODS OF MODULATING RNA STABILITY | DUKE UNIVERSITY (US) | 2023-09-28 | — | — | WO | disclosed |
| WO-2023183887-A2 | COMPOSITIONS FOR AND METHODS OF MODULATING RNA STABILITY | DUKE UNIVERSITY (US) | 2023-09-28 | — | — | WO | disclosed |
| US-11753397-B2 | Cereblon binders for the degradation of ikaros | C4 THERAPEUTICS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753397-B2 | Cereblon binders for the degradation of ikaros | C4 THERAPEUTICS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-20070161578-A1 | Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and/or H3 receptor antagonist/inverse agonist | SCHERING CORPORATION | 2007-07-12 | — | — | US | disclosed |
| US-20070142369-A1 | Combination of an H3 antagonist/inverse agonist and an appetite suppressant | SCHERING CORPORATION | 2007-06-21 | — | — | US | disclosed |
| US-7220735-B2 | Benzimidazolone histamine H3 antagonists | SCHERING CORPORATION (US) | 2007-05-22 | — | — | US | disclosed |
| US-7199147-B2 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-03 | — | — | US | disclosed |
| US-7199147-B2 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-03 | — | — | US | disclosed |
| US-20070043051-A1 | Methods and compositions of novel triazine compounds | TIMMER RICHARD T | 2007-02-22 | — | — | US | disclosed |
| US-20070043051-A1 | Methods and compositions of novel triazine compounds | TIMMER RICHARD T | 2007-02-22 | — | — | US | disclosed |
| US-7179815-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2007-02-20 | — | — | US | disclosed |
| CN-1021328-C | PROCESS FOR PREPARING PYRIDAZINAMINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 1993-06-23 | — | — | CN | disclosed |
| CN-1033274-A | The preparation method of new Pyridazinyl amine derivative | JANSSEN PHARMACEUTICA NV (BE) | 1989-06-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142369-A1 | Combination of an H3 antagonist/inverse agonist and an appetite suppressant | CNR2, GPR119, GLP1R | ACHE 1191/4885CCR3 1133/4885SIGMAR1 238/4885 |
| US-20070043051-A1 | Methods and compositions of novel triazine compounds | AREG, TGFB1, PTGIS | ACHE 4413/4885CCR3 892/4885SIGMAR1 3025/4885 |
| US-20230381142-A1 | ANTILEISHMANIAL COMPOUNDS, COMPOSITIONS AND USE THEREOF | MPO, SSB, SGMS2 | ACHE 1245/4885CCR3 1668/4885SIGMAR1 1363/4885 |
| US-11753397-B2 | Cereblon binders for the degradation of ikaros | CRBN, IKZF1, IKZF3 | ACHE 3575/4885CCR3 3484/4885SIGMAR1 4335/4885 |
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | NFATC1, CTSS, MMP12 | ACHE 206/4885CCR3 2892/4885SIGMAR1 3709/4885 |
| US-20070161578-A1 | Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and/or H3 receptor antagonist/inverse agonist | NR1H4, NR1H3, NR1H2 | ACHE 2557/4885CCR3 1153/4885SIGMAR1 151/4885 |
| US-20230365530-A1 | QUINAZOLINE-2,4-DIAMINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING SAME AS ACTIVE INGREDIENT | EHMT2, EHMT1, HNMT | ACHE 1157/4885CCR3 4035/4885SIGMAR1 3916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.